Home/Pipeline/Danegaptide

Danegaptide

Diabetic Retinopathy

Phase 2Active

Key Facts

Indication

Diabetic Retinopathy

Phase

Phase 2

Status

Active

Company

Breye Therapeutics

About Breye Therapeutics

Breye Therapeutics is a Danish biotech advancing oral therapies for retinal diseases like diabetic retinopathy and age-related macular degeneration. Its lead asset, danegaptide, has reported positive Phase 1b data, and the company is also developing a platform of oral P2X7 receptor antagonists. With a seasoned leadership team and a focus on significant unmet needs in ophthalmology, Breye is positioning itself to address a large market with convenient oral alternatives to current invasive treatments.

View full company profile

Therapeutic Areas

Ophthalmology Retinal Diseases

Other Diabetic Retinopathy Drugs

Drug	Company	Phase	Status
Undisclosed Program (DR)	Cloudbreak Pharmaceutical	Pre-clinical / Clinical	In pipeline; uses ADS Platform
NOX4 Inhibitor (GLX7013114)	Glucox Biotech	Preclinical	Active
PER-001	Perfuse Therapeutics	Phase 2	Active
jCell (RPCs)	jCyte	Preclinical	Active
LumineticsCore	Digital Diagnostics	Approved	Active
Diabetic Retinopathy Program	Lxbio Pharmaceuticals	Pre-clinical	Active
Undisclosed	Hillhurst Biopharmaceuticals	Preclinical	Active
NBP-14 and derivatives	Neuro Bio	Research	Active
Vasculogenic Cell Therapy	Vascugen	Pre-clinical	Active
OcuRetina	Oculotix	Phase 2	Active
YH14618	Yuhan	Phase 2	Active